Keybanc Maintains Overweight on Castle Biosciences, Lowers Price Target to $25
Portfolio Pulse from richadhand@benzinga.com
Keybanc analyst Paul Knight has maintained an Overweight rating on Castle Biosciences (NASDAQ:CSTL) but lowered the price target from $37 to $25.

August 04, 2023 | 2:53 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Castle Biosciences' price target has been lowered from $37 to $25 by Keybanc, although the Overweight rating is maintained.
The lowering of the price target by Keybanc indicates a potential decrease in the stock's value. However, the maintained Overweight rating suggests that the stock is still expected to outperform. This mixed signal could lead to short-term uncertainty and potential downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100